These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 10586358)
1. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group]. Taue R; Kanayama H; Kagawa S Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358 [TBL] [Abstract][Full Text] [Related]
2. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P). Berruti A; Cerutti S; Fasolis G; Sperone P; Tarabuzzi R; Bertetto O; Pagani G; Zolfanelli R; Pallotti S; Bumma C; Fontana D; Rosseti SR; Dogliotti L; Angeli A Anticancer Res; 1997; 17(6D):4697-702. PubMed ID: 9494591 [TBL] [Abstract][Full Text] [Related]
3. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy. Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985 [TBL] [Abstract][Full Text] [Related]
4. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482 [TBL] [Abstract][Full Text] [Related]
5. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Xie W; Nakabayashi M; Regan MM; Oh WK Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608 [TBL] [Abstract][Full Text] [Related]
6. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. Schröder FH; Tombal B; Miller K; Boccon-Gibod L; Shore ND; Crawford ED; Moul J; Olesen TK; Persson BE BJU Int; 2010 Jul; 106(2):182-7. PubMed ID: 19912212 [TBL] [Abstract][Full Text] [Related]
7. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359 [TBL] [Abstract][Full Text] [Related]
8. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528 [TBL] [Abstract][Full Text] [Related]
9. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571 [TBL] [Abstract][Full Text] [Related]
11. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?]. Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988 [TBL] [Abstract][Full Text] [Related]
12. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers. Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350 [TBL] [Abstract][Full Text] [Related]
13. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. Noguchi M; Noda S J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307 [TBL] [Abstract][Full Text] [Related]
14. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. Miyake H; Hara I; Eto H BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer. Miyake H; Hara I; Yamazaki H; Eto H Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973 [TBL] [Abstract][Full Text] [Related]
18. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Okegawa T; Kinjo M; Nutahara K; Higashihara E Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552 [TBL] [Abstract][Full Text] [Related]
19. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients. Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ; Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070 [TBL] [Abstract][Full Text] [Related]
20. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]